Vacunas (English Edition)最新文献

{"title":"Broadening criteria for palivizumab administration does not reduce admissions for respiratory syncytial virus","authors":"Jessica Gómez Ávila,&nbsp;Juan Iñigo Gil,&nbsp;Beatriz Flores Méndez","doi":"10.1016/j.vacune.2024.02.004","DOIUrl":"https://doi.org/10.1016/j.vacune.2024.02.004","url":null,"abstract":"<div><h3>Introduction</h3><p>Respiratory syncytial virus is the leading cause of hospital admission for bronchiolitis in Spain. Immunoprophylaxis with palivizumab is an effective measure in those patients who meet the criteria for its administration. The aim of our study was to evaluate whether the extension of these criteria would reduce the rate of hospitalisation for this reason.</p></div><div><h3>Methods</h3><p>A retrospective analytical observational case–control study was conducted in a tertiary hospital, including 338 neonates born between 2017 and 2022. The “controls” arm included patients with criteria for palivizumab administration according to the Spanish Society of Neonatology indications and the “cases” arm included preterm patients up to 35 weeks of gestational age excluded from these criteria. The main variables assessed were the occurrence of RSV-positive bronchiolitis and the need for admission in both groups.</p></div><div><h3>Results</h3><p>The incidence of RSV bronchiolitis and admission to the hospital ward in the case group was similar to that found in our palivizumab-immunised population (control group).</p><p>Statistically significant differences were only found for the presence of school-aged siblings as a risk factor for the development of bronchiolitis.</p></div><div><h3>Conclusions</h3><p>An extension of the criteria for palivizumab administration to all preterm infants younger than 35 weeks would lead to increased costs without a reduction in infection rates and respiratory syncytial virus admissions.</p></div><div><h3>Introducción</h3><p>El virus sincitial respiratorio supone la primera causa de ingreso hospitalario por bronquiolitis en nuestro medio. La inmunoprofilaxis con palivizumab es una medida efectiva en aquellos pacientes que cumplen criterios para su administración. El objetivo de nuestro estudio es evaluar si la ampliación de dichos criterios disminuiría la tasa de hospitalización por este motivo.</p></div><div><h3>Métodos</h3><p>Se realizó un estudio observacional analítico retrospectivo de tipo casos y controles desarrollado en un hospital de tercer nivel, que incluía 338 neonatos nacidos entre los años 2017 a 2022. En el brazo «controles» se incluyeron pacientes con criterios de administración de palivizumab según indicaciones de la Sociedad Española de Neonatología y en el brazo «casos», pacientes prematuros de hasta 35 semanas de edad gestacional excluidos de estos criterios. Se evaluaron como variables principales la aparición de bronquiolitis VRS positiva y la necesidad de ingreso en ambos grupos.</p></div><div><h3>Resultados</h3><p>La incidencia de bronquiolitis por virus respiratorio sincitial y el ingreso en planta de hospitalización en el grupo de casos fue similar a la encontrada en nuestra población inmunizada con palivizumab (grupo control).</p><p>Solo se encontró diferencia estadísticamente significativa en cuanto a la presencia de hermanos en edad escolar como factor de riesgo para el desar","PeriodicalId":101272,"journal":{"name":"Vacunas (English Edition)","volume":"25 1","pages":"Pages 71-77"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140135118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic variants rs1800629 in TNF and rs2228145 in IL6R: Association with adverse event following immunisation (AEFI) and SARS-CoV-2 neutralising antibodies in western Mexico population that received AZD1222 vaccine","authors":"Axel Jair Villa-Panduro ,&nbsp;Narda M. Corona-Reynaga ,&nbsp;Dennis A. Meza-Peña ,&nbsp;Mayra Alejandra Enciso Ramírez ,&nbsp;Astrid Selene Espinoza García ,&nbsp;Jorge Galindo-García ,&nbsp;Berenice Sanchez-Caballero ,&nbsp;Elia Herminia Valdés-Miramontes ,&nbsp;José Francisco Muñoz-Valle ,&nbsp;Zyanya Reyes-Castillo","doi":"10.1016/j.vacune.2024.02.017","DOIUrl":"https://doi.org/10.1016/j.vacune.2024.02.017","url":null,"abstract":"<div><h3>Introduction</h3><p>In this research, we evaluated the association of genetic variants rs1800629 in <em>TNF</em> and rs2228145 in <em>IL6R</em> with production of neutralising antibodies against SARS-CoV-2 and the frequency of adverse effects following immunisation (AEFIs) in adult population from Western of Mexico that received AZD1222 vaccination.</p></div><div><h3>Methods</h3><p>117 adults were evaluated [33 years (23–40), 65% women]. The self-reported frequency of AEFIs was recorded and the percentage of post-vaccination neutralising antibodies was quantified. The identification of rs1800629 variant in <em>TNF</em> and rs2228145 in <em>IL6R</em> was performed by qPCR.</p></div><div><h3>Results</h3><p>The genotype frequencies of rs1800629 variant were: GG (86%) and GA (14%), and for rs2228145 variant were: AA (20%), CA (48%), and CC (32%). The percentage of post-vaccination antibodies was similar between men and women (median, 97.24%). An association was found between the frequency of AEFIs with the sex; being adynamia (<em>P</em> <!-->=<!--> <!-->.0243), chills (<em>P</em> <!-->=<!--> <!-->.0085), arthralgia (<em>P</em> <!-->=<!--> <!-->.0227), and pain in application area (<em>P</em> <!-->=<!--> <!-->.0096) more frequent in women. The GA genotype of rs1800629 variant showed an association with fever (<em>P</em> <!-->=<!--> <!-->.0131) and arthralgia (<em>P</em> <!-->=<!--> <!-->.0058) post-vaccination, but no relationship was found with the production of neutralising antibodies after AZD1222 vaccination. The rs2228145 variant was not associated with the production of antibodies nor with the AEFIs reported.</p></div><div><h3>Conclusion</h3><p>The genetic variants rs1800629 in <em>TNF</em> and rs222815 in <em>IL6R</em> are not associated with the production of neutralising antibodies against SARS-CoV-2 after receiving AZD1222 scheme in population from western of Mexico; however, the results suggest that rs1800629 variant increases the frequency of post-vaccination events, particularly fever and arthralgia.</p></div>","PeriodicalId":101272,"journal":{"name":"Vacunas (English Edition)","volume":"25 1","pages":"Pages 78-87"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140135119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaccine hesitancy: An introduction to its concept","authors":"Luis Salleras ,&nbsp;Montserrat Salleras ,&nbsp;Diana Toledo ,&nbsp;Àngela Domínguez","doi":"10.1016/j.vacune.2024.02.001","DOIUrl":"https://doi.org/10.1016/j.vacune.2024.02.001","url":null,"abstract":"","PeriodicalId":101272,"journal":{"name":"Vacunas (English Edition)","volume":"25 1","pages":"Pages 1-4"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140133960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delving into revolutionary SARS-CoV-2 vaccine approaches: Molecular and virological examinations; principles of SARS-CoV-2 vaccine platform","authors":"Fahime Edalat ,&nbsp;Fatemeh Hosseini Tabatabaie ,&nbsp;Afagh Moattari ,&nbsp;Arash Letafati ,&nbsp;Jamal Sarvari ,&nbsp;Seyed Younes Hosseini","doi":"10.1016/j.vacune.2024.02.013","DOIUrl":"https://doi.org/10.1016/j.vacune.2024.02.013","url":null,"abstract":"<div><p>Coronavirus disease (COVID-19) is an infectious illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It emerged in 2019 and quickly became a global pandemic, resulting in numerous deaths worldwide. Despite the devastating impact of SARS-CoV-2 on human life, it also spurred the development of advanced vaccine platforms. Within a remarkably short time frame, 11 vaccines have been approved for human use, marking a significant historical achievement. These include mRNA, whole inactivated, recombinant protein, and adenoviral vector platforms. Notably, these new-generation vaccine platforms represent a departure from previously utilized methods and form the backbone of SARS-CoV-2 preventive strategies. In order to enhance the efficacy of vaccines, it is crucial to have a comprehensive understanding of their underlying virological and immunological characteristics. The recent emergence of variant strains, particularly the Omicron variant, has raised doubts regarding the effectiveness of current vaccines and emphasized the need for a universal platform for future vaccinations.</p><p>This review focuses on discussing various vaccine platforms based on their molecular design, their ability to stimulate the immune system, safety concerns, potential efficacy against viral variants, and prospects for the future.</p></div>","PeriodicalId":101272,"journal":{"name":"Vacunas (English Edition)","volume":"25 1","pages":"Pages 109-127"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140134499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent advancements in cancer vaccines: A systematic review","authors":"Stuti Srivastava ,&nbsp;Devendra Singh ,&nbsp;Sunil Kumar Verma ,&nbsp;Minakshi Pandey ,&nbsp;Avinash Sharma ,&nbsp;Himanshu Pandey ,&nbsp;Anshu Mishra","doi":"10.1016/j.vacune.2024.02.011","DOIUrl":"https://doi.org/10.1016/j.vacune.2024.02.011","url":null,"abstract":"<div><p>Cancer is a versatile and common disease that occurs as a result of the uncontrolled growth as well as the spread of abnormal cells in the human body. Its history spans thousands of years, from the first descriptions of ancient civilizations to the advancement of modern science. His research throughout the 20th and 21st centuries revealed the genetic and molecular mechanisms of growth and development. Treatment options are diverse and include surgery, radiation, chemotherapy, chemotherapy, and immunotherapy. Despite great progress, cancer remains a global health problem. Research is ongoing to further unravel the complexity of this disease to improve early diagnosis, personalized treatment strategies, and achieve better patient outcomes. This study provides a general definition, diagnosis, treatment, and course of cancer and attempts to determine whether it is beneficial or harmful to humans.</p></div>","PeriodicalId":101272,"journal":{"name":"Vacunas (English Edition)","volume":"25 1","pages":"Pages 97-108"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140135094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaccination impact on long COVID sequelae; a perspective view","authors":"Farhad Dadgar ,&nbsp;Fatemeh Dehghani ,&nbsp;Farzaneh Peikfalak ,&nbsp;Masoud Keikha","doi":"10.1016/j.vacune.2024.02.005","DOIUrl":"https://doi.org/10.1016/j.vacune.2024.02.005","url":null,"abstract":"","PeriodicalId":101272,"journal":{"name":"Vacunas (English Edition)","volume":"25 1","pages":"Pages 147-148"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140135095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Simultaneous detection and genomic characterization of Zika virus Protein M, E and NS1 using optimized primers from Asian and African Lineage","authors":"Muhammed Mustapha Suleiman ,&nbsp;Olatunji Matthew Kolawole","doi":"10.1016/j.vacune.2024.02.008","DOIUrl":"https://doi.org/10.1016/j.vacune.2024.02.008","url":null,"abstract":"<div><h3>Purpose</h3><p>Despite positive serological outcome, molecular confirmations have encountered little/no success either due to protocol accuracy, primer targets, or choice of sample amongst others. This study aims at providing an optimized protocol for the molecular detection of Zika virus amongst serologically positive respondent using samples from 2 selected hospitals in North Central Nigeria.</p></div><div><h3>Materials and methods</h3><p>About five (5) ml of blood samples was collected from a total of 400 participants for serological analysis, the IgM-positive samples were processed for molecular analysis using target primers from Asian and African lineage while a structured questionnaire was used to evaluate risk factors.</p></div><div><h3>Results</h3><p>Prevalence of 19% (38) and 45% (90) IgM and IgG positivity was recorded amongst respondent in Federal Medical Center (FMC), Keffi (R² <!-->=<!--> <!-->1) while 36% (72) and 42% (84) was recorded in General Hospital (GH), Minna (R² <!-->=<!--> <!-->1). The respective risk factors such as proximity of respondent to stagnant water or drainage channel, frequency of mosquito bite, prevention strategy, implementation of the prevention strategies for mosquito, and consumption of bushmeat were significant at set standard of <em>P</em> <!-->&lt;<!--> <!-->0.05. Molecular quantification revealed cut-off values (Ct) from 21.73 to 25.75 for all the 3 targeted protein while sequence analysis showed relatedness to deposited sequences in GenBank.</p></div><div><h3>Conclusions</h3><p>The abundance of the viral proteins as well as the genetic relatedness is indicative of presence of multiple strains of the virus or conservation of region across different geolocations. In lieu of the outcome, primers from multiple lineages is thereby recommended to forestall/overcome the challenge of cross-reactivity/false-negativity with Zika virus detection.</p></div>","PeriodicalId":101272,"journal":{"name":"Vacunas (English Edition)","volume":"25 1","pages":"Pages 40-45"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140134496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prevalence of post-COVID-19 vaccination syndrome and quality of life among COVID-19-vaccinated individuals","authors":"Yogendra Shrestha,&nbsp;Rajesh Venkataraman","doi":"10.1016/j.vacune.2024.02.010","DOIUrl":"https://doi.org/10.1016/j.vacune.2024.02.010","url":null,"abstract":"<div><h3>Background</h3><p>There were many studies conducted to determine how immunization affects people with long-term COVID. The results of those studies have caused debate as they gave rise to varying outcomes. Some evidence indicates a change in, an improvement in, a continuation of, or even a worsening of long-term COVID symptoms following vaccination. The ratio of change in antibody titers was noticeably larger in the group of people whose illnesses became worse. Hence, this study aimed to explore potential post-COVID-19 vaccination syndrome (PCVS) in vaccinated individuals and also to assess their quality of life (QoL).</p></div><div><h3>Methodology</h3><p>Between September 2021 and May 2023, an ambidirectional, descriptive, follow-up cohort study was conducted, enrolling participants who were 18 years of age or older, met the vaccination requirements established by the Ministry of Health and Family Welfare, Government of India, and had completed the primary immunization series with the AZD1222® or BBV152® vaccine. The prevalence of PCVS and the QoL measured using EQ-5D-5L were assessed at 1 month, 6 months, and 12 months post-COVID-19 vaccination.</p></div><div><h3>Results</h3><p>AZD1222® vaccine was received by 84.28% (343) of the participants, and BBV152® vaccine was received by 15.72% (64) of the study participants. <em>A month after the primary vaccination series</em>, 52.8% (215) of the total participants had at least 1 PCVS, 39.8% (162) at 6 months, and 64.6% (263) at 12 months. Among those who had received vaccinations, the QoL increased at 6 months to 0.975<!--> <!-->±<!--> <!-->0.08 and declined at 12 months to 0.94<!--> <!-->±<!--> <!-->0.13 from 0.949<!--> <!-->±<!--> <!-->0.13 at 1 month after receiving a primary immunization. The overall prevalence of PCVS between AZD1222®-vaccinated individuals and BBV152®-vaccinated individuals at a month post-vaccination was 54.5% vs. 43.8%, at 6 months it was 41.1% vs. 32.8%, and at 12 months it was 65.59% vs. 59.4%. The QoL between AZD1222®-vaccinated individuals and BBV152®-vaccinated individuals at a month post-vaccination was 0.95<!--> <!-->±<!--> <!-->0.13 vs. 0.95<!--> <!-->±<!--> <!-->0.126, at 6 months it was 0.98<!--> <!-->±<!--> <!-->0.08 vs. 0.97<!--> <!-->±<!--> <!-->0.07, and at 12 months it was 0.94<!--> <!-->±<!--> <!-->0.12 vs. 0.92<!--> <!-->±<!--> <!-->0.20. However, there was no statistically significant difference in the prevalence of PCVS and QoL between AZD1222® and BBV152®-vaccinated individuals.</p><p>The percentage of participants who had at least one PCVS was 83.9% (146) in the group that got booster doses and 50.2% (117) in the group that did not. The QoL was 0.9<!--> <!-->±<!--> <!-->0.15 in the group receiving booster dosages and 0.96<!--> <!-->±<!--> <!-->0.11 in the group not receiving them. There was a statistically significant difference in the prevalence of PCVS and QoL between booster dose recipients and no booster dose recipients.</p></div><div><h3>Con","PeriodicalId":101272,"journal":{"name":"Vacunas (English Edition)","volume":"25 1","pages":"Pages 7-18"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140135091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of HCV among patients with HIV in Iran: A systematic review and meta-analysis","authors":"Maedeh Hajizadeh ,&nbsp;Maryam Moradi Binabaj ,&nbsp;Arezoo Asadi ,&nbsp;Milad Abdi ,&nbsp;Abolfazl Shakiba ,&nbsp;Masoumeh Beig ,&nbsp;Mohsen Heidary ,&nbsp;Mohammad Sholeh","doi":"10.1016/j.vacune.2024.02.014","DOIUrl":"https://doi.org/10.1016/j.vacune.2024.02.014","url":null,"abstract":"<div><h3>Background</h3><p>Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections are major public health issues worldwide. The present study aimed to estimate the prevalence of HCV among patients with HIV in Iran and evaluate the demographic and behavioral factors associated with a heterogeneity of results.</p></div><div><h3>Methods</h3><p>MEDLINE (via PubMed), Web of Science, SCOPUS, Google Scholar, Embase, and 2 Persian databases, including Scientific Information Database (SID) and Magiran, were used for a systematic search from January 1, 2005 to February 26, 2022. Data were analyzed according to country, publication time, enrolment time, number of patients, gender, mean age, HIV/HCV diagnosis method, and HIV/HCV treatment. The analysis was carried out using R and the metafor package.</p></div><div><h3>Results</h3><p>We found that 60.94 (95% CI 54.59–67.11) HIV-infected people in Iran were co-infected with HCV. The greatest burden of this co-infection was in the Hamedan 86.67 (62.12, 96.26), Kashan 85.71 (75.03, 92.30), followed by the Kerman 73.94(66.75, 80.04). The lowest prevalence of HBV-HCV co-infection was observed in Kermanshah at 11.91 (9.98, 13.98).</p></div><div><h3>Conclusion</h3><p>HBV-HCV co-infection is a challenging and important medical condition because of its variable clinical manifestations, increased risk of cirrhosis and HCC, and unpredictable treatment response. Due to the heterogeneous distribution pattern of HBV–HCV infection in Iran, continuous prevention and control measurements and the implementation of further epidemiologic studies are necessary.</p></div>","PeriodicalId":101272,"journal":{"name":"Vacunas (English Edition)","volume":"25 1","pages":"Pages 128-139"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140135096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaccine hesitancy in healthcare professionals and health sciences students of the last courses","authors":"Sergi Gomez ,&nbsp;Pere Godoy","doi":"10.1016/j.vacune.2024.02.015","DOIUrl":"10.1016/j.vacune.2024.02.015","url":null,"abstract":"<div><h3>Objective</h3><p>To evaluate the vaccination hesitancy of health professionals and students in the last courses of the medical and nursing degrees.</p></div><div><h3>Material and method</h3><p>Cross-sectional study in which the data of the students of the last courses of the main universities of Lleida and Barcelona and of the doctors and nurses teaching staff of them have been collected. The collection was done through a previously validated questionnaire about their opinions regarding different aspects of the vaccines and the fact of having delayed or refused the administration of a vaccine. The dependent variable was vaccine hesitancy and its association with the main independent variables was determined with the odds ratio (OR) and its 95% confidence interval (CI). The ORs were adjusted using logistic regression models.</p></div><div><h3>Results</h3><p>A 33% of vaccine hesitancy has been found among health professionals and students in the last courses, with 12% of people who have refused the administration of any vaccine. It is higher in women and nurses. The main rejected vaccines have been, in order, flu, COVID, and HPV and the main reasons, not believing them necessary, safe or effective.</p></div><div><h3>Conclusions</h3><p>Up to a third of health professionals or students have vaccine hesitancy, especially nursing staff, the main collective in charge of administering vaccines who, according to other studies, have more relevance in population vaccination hesitancy.</p></div>","PeriodicalId":101272,"journal":{"name":"Vacunas (English Edition)","volume":"25 1","pages":"Pages 54-63"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140082388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}